-
Thematic Analysis
NewPower M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Power Sector
-
Product Insights
NewNet Present Value Model: Enanta Pharmaceuticals Inc’s EDP-514
Empower your strategies with our Net Present Value Model: Enanta Pharmaceuticals Inc's EDP-514 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
EDP Renovaveis Anhui Distributed Generation Solar PV Park, China
Empower your strategies with our EDP Renovaveis Anhui Distributed Generation Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the project’s core details and stages...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
EDP Renewables Cuenca Solar PV Park, Spain
Empower your strategies with our EDP Renewables Cuenca Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the project’s core details and stages of development.....
-
Product Insights
EDP Renewables Huelva Solar PV Park, Spain
Empower your strategies with our EDP Renewables Huelva Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the project’s core details and stages of development.....
-
Product Insights
NewNet Present Value Model: Enanta Pharmaceuticals Inc’s EDP-938
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-938 in Respiratory Syncytial Virus (RSV) Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDP-938 in Respiratory Syncytial Virus (RSV) Infections Drug Details: EP-938 is under development for the...